Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Shen

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Lancet. Respiratory Medicine|July 2, 2021
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE studySteven D Nathan, Aaron Waxman, Sudarshan Rajagopal, et al.
Chest|December 2, 2024
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular ComorbiditiesR James White, Karim El-Kersh, Stephan Rosenkranz, et al.
BMJ Open Respiratory Research|March 22, 2024
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE studyJason Weatherald, Steven D Nathan, Karim El-Kersh, et al.
Respiratory Medicine|August 2, 2023
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinilChad E Miller, Veronica Franco, Jimmy S Smith, et al.
Pulmonary Circulation|August 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertensionSylvia M Nikkho, Manuel J Richter, Eric Shen, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Lancet. Respiratory Medicine|July 2, 2021
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE studySteven D Nathan, Aaron Waxman, Sudarshan Rajagopal, et al.
Chest|December 2, 2024
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular ComorbiditiesR James White, Karim El-Kersh, Stephan Rosenkranz, et al.
BMJ Open Respiratory Research|March 22, 2024
Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE studyJason Weatherald, Steven D Nathan, Karim El-Kersh, et al.
Respiratory Medicine|August 2, 2023
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinilChad E Miller, Veronica Franco, Jimmy S Smith, et al.
Pulmonary Circulation|August 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertensionSylvia M Nikkho, Manuel J Richter, Eric Shen, et al.
Pageof 5